摘要
目的观察黄葵胶囊干预非增殖性视网膜病变(NPDR)的临床疗效和对黄斑中心凹视网膜厚度(μm)、浅层视网膜及深层视网膜毛细血管丛的血管密度的影响。方法将62例符合条件的患者按随机数字表法分为对照组(31例,62眼)和观察组(31例,62眼)。对照组口服羟苯磺酸钙片治疗,观察组加服黄葵胶囊,一个月为一个疗程,6个疗程后评价治疗效果;治疗前后分别进行眼底及视力检查,利用光学相干断层扫描血管成像(OCTA)观察黄斑中心凹视网膜神经上皮层厚度及浅层视网膜及深层视网膜毛细血管丛的血管密度变化。结果观察组治疗效果优于对照组(93%VS 74%,P<0.05);观察组黄斑中心凹视网膜厚度变化明显优于对照组(P<0.05);观察组浅层视网膜及深层视网膜毛细血管丛的血管密度治疗效果优于对照组(P<0.05)。结论黄葵胶胶囊治疗本病疗效显著,值得临床推广应用。
Objective To observe the clinical efficacy of Huangkui capsules in interfering with non-proliferative retinopathy and the effect on macular foveal retinal thickness(μm),superficial and deep retinal capillary plexus vascular density.Methods 62 eligible patients were randomly divided into control group(31 cases,62 eyes)and observation group(31 cases,62 eyes).The control group was treated with calcium dobesilate tablets,the observation group was given Huangkui capsules,1 month for 1 course,and the treatment effect was evaluated after 6 courses.Before and after treatment,visual acuity test,fundus examination,optical coherence tomography angiography(OCTA)were used to observe the thickness of the retinal neuroepithelial layer of the macular fovea and the blood vessel density changes of the superficial and deep retinal capillary plexus.Results The effective rate of the observation group was better than that of the control group(93%VS 74%,P<0.05).The change of macular foveal retinal thickness in the observation group was notable higher than that in the control group(P<0.05).Vascular density of the superficial and deep retinal capillary plexus in the observation group was better than that in the control group(P<0.05).Conclusion Huangkui capsule has a significant effect in the treatment this disease,which is worthy of clinical application.
作者
钱语
马幸
戴荣峰
QIAN Yu;MA Xing;DAI Rongfeng(Department of Endocrinology,Changzhou Third People's Hospital,Jiangsu Province,Changzhou 213000,China)
出处
《光明中医》
2021年第15期2489-2492,共4页
GUANGMING JOURNAL OF CHINESE MEDICINE
